ASH 2013

Novel STAT5 Targets FasL in AML

Experts discuss miR-590, a novel STAT5 oncogenic miRNA that targets FasL in AML.

AE Reporting Sensitivity Relatively Low in Cooperative Group Trials


The current system of AE reporting has modest sensitivity and a demonstrable false positive rate in cooperative group trials.

Biomarkers, AlloHSCT Predict Post-AML Relapse Prognosis


Cytogenetic and molecular abnormalities may also be prognostic of post-relapse prognosis.

Leukemia, B-cell Lymphoma Management Not Always Evidence Based


Clinical practices does not always reflect evidence-based expert opinion when it comes to management of acute or chronic myeloid leukemia (AML, CML) and B-cell lymphomas.

Ponatinib Shows Promise for Resistant Ph+ Leukemia


Ponatinib shows "early, deep and durable" molecular responses among patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

FCR Chemoimmunotherapy Improved EFS in High-Risk, Early-Stage CLL


Fludarabine, cyclophosphamide and rituximab (FCR) chemoimmunotherapy is associated with improved event-free survival in patients with high-risk, early-stage CLL.

Oral IPI-145 PI3K Inhibitor Shows Promising Activity in Relapsed/Refractory CLL


Clinical activity has been observed in patients with relapsed/refractory CLL at all doses of IPI-145 studied, from 8 mg to 75 mg twice daily.

Novel Proteasome Inhibitor Elicits Response in Multiple Myeloma Patients

Ixazomib citrate plus lenalidomide/dexamethasone active in newly diagnosed multiple myeloma.

Gemtuzumab Ozogamicin Reduces Pediatric AML Relapse Risk

Adding gemtuzumab ozogamicin to standard therapy improved event-free survival improved in children with de novo acute myeloid leukemia.

Dendritic Cell Vaccine Prolongs Chemotherapy-induced AML Remission for Some Patients


Dendritic cell vaccination after chemotherapy-induced remission in acute myeloid leukemia has a "demonstrable" anti-relapse effect for some high-risk patient, according to data presented at ASH 2013.

CTL019 Cells Can Induce Potent, Durable Responses in Relapsed/Refractory ALL


CTL019 cells can induce potent and durable responses in children and adults with relapsed/refractory acute lymphoblastic leukemia, according to results of a pilot study reported at ASH 2013.

Obinutuzumab Plus Chlorambucil Highly Active in Patients with Treatment-naïve CLL, Comorbidities


Obinutuzumab (GA101) plus chlorambucil significantly prolonged PFS in treatment-naïve patients with chronic lymphocytic leukemia and co-existing medical conditions, according to data presented at ASH 2013.

T-cell Depleted HSCT Associated with Lower GVHD Rates in ALL


For adults with ALL, ex-vivo T-cell depleted allogenic HCT is associated with a lower rate of graft versus host disease than conventional, unmodified allografts, according to data presented at ASH 2013.

CTL019-targeting T-cell Therapy Promising Against Advanced, Refractory CLL, ALL


CTL019 T cells engineered to express chimeric antigen receptor, which targets CD19, show promise against advanced, refractory CLL and pediatric pre-B-cell ALL, according to research presented at ASH 2013.

Lenalidomide/Low-dose Dexamethasone Improves PFS in Newly Diagnosed Multiple Myeloma


Continuous treatment with lenalidomide and low-dose dexamethasone has been established as a new standard of care for patients with newly diagnosed multiple myeloma who are ineligible for SCT, according to data presented at ASH 2013.

Denosumab May Be Effective Against Hypercalcemia of Malignancy


Subcutaneous denosumab is associated with strong serum calcium responses among patients with hypercalcemia of malignancyfollowing IV bisphosphonate treatment, found research at ASH 2013.

Donor-derived Anti-CD19 CAR T cells Show Promise Against Post-transplant B-cell Malignancies


Genetically modified donor-derived anti-CD19 CAR-expressing T-cell infusions were followed by regression of B-cell malignancies that had persisted after alloHSCT, according to research presented at ASH 2013.

Engineered CAR T Cells Achieve Remissions in Diffuse Large B-cell Lymphoma


Infusions of autologous T cells genetically modified to express a chimeric antigen receptor that targets B-cell antigen CD19 were associated with at least partial remissions in patients with chemotherapy-refractory diffuse large B-cell lymphoma, found research at ASH 2013.

Siltuximab Offers 'Durable' Tumor and Symptom Responses in Multicentric Castleman's Disease


Siltuximab improves symptoms and clinical outcomes for patients with multicentric Castleman's disease, despite a high rate of drug discontinuation due to toxicities, according to data presented at ASH 2013.

Bortezomib Associated with Low Risk of Heart Failure in Patients with Multiple Myeloma


Bortezomib was associated with a low rate of grade 3 or higher heart failure in patients with multiple myeloma treated in upfront or relapsed and/or refractory settings, found research at ASH 2013.

Higher Cumulative Bortezomib Dose Associated with Longer OS in Multiple Myeloma


Higher cumulative doses of bortezomib are associated with improved overall survival among patients with previously untreated multiple myeloma, found research presented at ASH 2013.

Adding Midostaurin Improves Response in Patients with FLT3-ITD-positive AML


Rates of complete remission were promising in patients with FLT3-ITD-positive acute myeloid leukemia when midostaurin was added to intensive induction therapy, according to data presented at ASH 2013.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs